Study guide
2.8 Medication Reconciliation & Ordering Monitoring Procedures
California Practice Standards and Jurisprudence Examination for Pharmacists CPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Information & Prescription Evaluation (Domain 1)
1.1 Patient Profile & Health Data Acquisition 1.2 Prescription Authenticity & Prescriber Authority 1.3 California Security Prescription Forms & E-Prescribing Mandates (B&P § 688) 1.4 Clinical Evaluation of Dosing & Organ Impairment 1.5 Drug-Drug & CYP450 Interactions 1.6 Special Populations & High-Risk Medications 1.7 Physical Assessment & Health Screening 1.8 Final Check, Labeling Verification & Product Selection Workflow
2 Chapter 2: Clinical Practice & Disease State Management (Domain 2: Clinical Practice & Jurisprudence)
2.1 Cardiovascular Therapeutics & Clinical Law 2.2 Endocrine & Metabolic Disorders 2.3 Respiratory & Infectious Disease Management 2.4 Central Nervous System & Pain Management 2.5 Oncology, Immunology & Specialty Pharmacy 2.6 Medication Therapy Management & Collaborative Goals of Therapy 2.7 Formulary Systems, Therapeutic Interchange & Medication Affordability 2.8 Medication Reconciliation & Ordering Monitoring Procedures
3 Chapter 3: California Pharmacy Jurisprudence & Prescriptive Authority (Domain 2: Clinical Practice & Jurisprudence)
3.1 Controlled Substances & CURES PDMP 3.2 Controlled Substance Dispensing, Refills, & Partial Fills 3.3 Independent Pharmacist Furnishing Scope 3.4 Advanced Pharmacist Practitioner (APP/APh) & CDTM 3.5 Immunization Authority & CAIR Reporting 3.6 Patient Counseling & Patient-Centered Labeling 2.9 OTC, CAM, Lifestyle Counseling & Teach-Back 2.10 Educating Health Professionals & Supplemental Patient Information
4 Chapter 4: Pharmacy Operations, Board Governance & Personnel (Domain 3: Pharmacy Operations & Jurisprudence)
California Board of Pharmacy Governance & Licensure Pharmacist Continuing Education & License Maintenance Pharmacist-in-Charge (PIC) & Pharmacy Ownership Pharmacy Personnel & Supervision Ratios Pharmacy Security, Theft, & Diversion Reporting 4.6 Controlled Substance Inventory & Record Reconciliation 4.7 Quality Assurance, Medication Error Systems & ADR Reporting 4.8 Privacy, Confidentiality & Pharmacy Policies and Procedures
5 Chapter 5: Drug Supply Chain, Dispensing & Compounding Regulations (Domain 3: Pharmacy Operations & Jurisprudence)
5.1 Drug Procurement, DSCSA Track & Trace, & Storage 5.2 Generic Substitution, Bioequivalence, & Orange Book 5.3 Prescription Transfer, Refills, & Off-Site Dispensing 5.4 Non-Sterile Compounding Standards 5.5 Sterile Compounding & Hazardous Drug Handling 5.6 Emergency Preparedness & Continuity of Pharmacy Operations
2.8 Medication Reconciliation & Ordering Monitoring Procedures
Key Takeaways Explain This Topic AI
Medication reconciliation compares the best possible medication history against orders at every transition of care, with heightened rigor for high-risk hospitalized patients on anticoagulants, insulin, opioids, and narrow-therapeutic-index drugs.
Under B&P § 4052(a), California pharmacists may order and interpret tests to monitor drug efficacy and toxicity; facility protocols (B&P §§ 4052.1–4052.2) and APh authority (B&P § 4052.6) further define independent lab and therapy management scope.
Monitoring plans should be drug-specific: renal/hepatic function, glucose, EKG/QTc, and therapeutic drug levels must be timed correctly and acted on—not merely ordered.
Abnormal or actionable results must be communicated promptly to the patient (when appropriate) and the care team, with documentation of the finding, clinical interpretation, and follow-up plan.
Last updated: July 2026
Medication Reconciliation & Ordering Monitoring Procedures
Medication reconciliation and laboratory monitoring sit at the intersection of clinical judgment and California practice authority. Outline tasks 2A13 and 2A14 expect you to build an accurate medication list, resolve discrepancies before harm occurs, and ensure the right labs or diagnostic tests are ordered, interpreted, and communicated. On the CPJE, scenarios often combine a transition-of-care miss with a monitoring gap—treat both as pharmacist-owned problems.
Medication Reconciliation: Process and High-Risk Focus
Medication reconciliation is a structured comparison of a patient’s best possible medication history (BPMH) against medication orders at every transition of care: admission, transfer between units or levels of care, and discharge. The goal is not a clerical copy of what was on the last discharge summary; it is a verified, current list of what the patient was actually taking, then an intentional decision to continue, hold, modify, or discontinue each agent.
Building the Best Possible Medication History
Effective reconciliation draws from multiple sources because no single source is complete:
Patient or caregiver interview — ask about prescription drugs, OTC products, herbals/CAM, injectables, inhalers, eye drops, patches, and as-needed medications with actual doses and frequencies.
Pharmacy fill history / PDMP (CURES) — especially useful for controlled substances and recent opioid or benzodiazepine patterns.
Prior discharge summaries, ambulatory EHR medication lists, and bottle/photo review when available.
Allergy and ADR history — distinguish true hypersensitivity from intolerance so clinically needed drugs are not permanently blocked.
Document unresolved discrepancies (e.g., patient reports taking warfarin 5 mg daily but home list shows 2.5 mg) and escalate before the wrong dose is continued in the hospital.
High-Risk Hospitalized Patients
The outline specifically flags high-risk hospitalized patients . Heighten scrutiny when the regimen includes:
Anticoagulants / antiplatelets — wrong hold or restart timing drives thrombosis or bleeding.
Insulin and other hypoglycemics — home basal rates often do not translate 1:1 to inpatient nutrition and illness.
Opioids, benzodiazepines, and other CNS depressants — risk of respiratory depression, especially with new sedatives.
Narrow therapeutic index drugs — digoxin, lithium, phenytoin, aminoglycosides, vancomycin, immunosuppressants.
Renally cleared high-alert agents in AKI or fluctuating CrCl.
Classic CPJE traps include continuing a home ACE inhibitor and diuretic during acute kidney injury, missing that a patient was on a DOAC at home when bridging with heparin, or restarting a full home opioid regimen in an opioid-naïve postoperative patient after a prolonged NPO period. At discharge, reconciliation must produce a clear list for the patient and the next provider: what changed, why, and what monitoring is still pending.
Recommending and Ordering Monitoring Procedures
Outline task 2A14 covers recommending or ordering monitoring such as renal/hepatic function, glucose, EKG, and drug levels . Monitoring is part of determining and managing the course of therapy—not an optional add-on.
Drug-Specific Monitoring Anchors
Monitoring Target Representative Situations Pharmacist Actions
Renal function (SCr, CrCl/eGFR, electrolytes) Vancomycin, aminoglycosides, DOACs, lithium, metformin, ACEI/ARB/ARNI, SGLT2i Dose adjust, hold nephrotoxins in AKI, recheck after initiation
Hepatic function (AST/ALT, bilirubin, albumin, INR) Statins, methotrexate, amiodarone, many antifungals Baseline and periodic LFTs; stop or reduce if hepatotoxicity
Glucose Insulin, corticosteroids, atypical antipsychotics, fluoroquinolones Sliding-scale review, hypoglycemia rescue plan
EKG / QTc Antipsychotics, macrolides, fluoroquinolones, methadone, ondansetron (cumulative risk) Baseline/repeat ECG when risk factors stack; avoid additional QT prolongers
Drug levels (TDM) Vancomycin, aminoglycosides, digoxin, lithium, phenytoin, immunosuppressants Correct timing (trough vs peak), interpret with clinical status
Therapeutic drug monitoring fails when the level is drawn at the wrong time (e.g., a “trough” drawn during an infusion) or when the number is filed without action. Always interpret levels with renal function, interacting drugs, and the patient’s clinical response.
California Authority to Order and Interpret Tests
California law explicitly supports pharmacist involvement in monitoring. Under Business and Professions Code (B&P) § 4052 , pharmacists may order and interpret tests for the purpose of monitoring and managing the efficacy and toxicity of drug therapies , performed in the course of treating a patient and in accordance with policies, procedures, or protocols of the applicable practice setting as required by statute. Related provisions expand the operational frame:
B&P § 4052.1 — in licensed health care facilities, pharmacists may perform specified clinical functions, including ordering drug therapy–related laboratory tests, pursuant to facility policies and appropriate training.
B&P § 4052.2 — similar collaborative/protocol-based functions in health care facilities, home health agencies, or clinics with physician oversight.
B&P § 4052.6 / § 4210 (Advanced Practice Pharmacist) — APh recognition expands authority to perform patient assessments and to order and interpret tests as part of advanced practice pharmacy, often paired with initiating, adjusting, or discontinuing drug therapy under collaborative agreements or authorized protocols.
Exam distinction: recommending a test to a prescriber is always within clinical practice. Independently ordering and interpreting tests is authorized in California when the pharmacist is acting within § 4052 and the applicable facility protocol, CPA, or APh scope—do not invent unlimited standalone diagnostic authority outside those frameworks. CLIA-waived point-of-care testing in pharmacies has additional licensing and training requirements when performed on-site.
Communicating Results and Closing the Loop
Ordering a lab without acting on it is a process failure. When results return:
Interpret in context — is the vancomycin AUC/trough high because of AKI, a drug interaction, or a mistimed draw?
Communicate to the care team — contact the prescriber or use the shared EHR with a clear recommendation (hold, reduce, repeat level, obtain ECG).
Inform the patient or representative when results change self-management (e.g., home INR plan, hypoglycemia precautions), consistent with counseling duties and care-setting rules.
Document the result, your clinical assessment, who was notified, and the agreed plan.
For hospitalized high-risk patients, reconciling the discharge medication list with pending monitoring (e.g., “repeat BMP in 3 days after starting spironolactone”) prevents ambulatory harm. In community practice, the same discipline applies when initiating pharmacist-furnished therapies or managing chronic medications under protocol: baseline labs, timed follow-up, and documented communication complete the monitoring cycle.